Daito Pharmaceutical Co (TSE:4577) Beneish M-Score: -2.46 (As of Jun. 26, 2026)


TSE:4577 Daito Pharmaceutical Co Ltd TSE:4577
71 GF Score
Price 円1,224.00
GF Value 円1,276.34
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Daito Pharmaceutical Co Beneish M-Score?

Daito Pharmaceutical Co TSE:4577 -1.37% 71 Beneish M-Score is -2.46 as of Jun. 26, 2026. GuruFocus rates TSE:4577 with a GF Score™ of 71/100 and a GF Value™ of 円1,276.34 (Fairly Valued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Daito Pharmaceutical Co ranks worse than 53.24% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.46 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Daito Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TSE:4577' s Beneish M-Score Range Over the Past 10 Years
Min: -2.75   Med: -2.6   Max: -2.29
Current: -2.46

During the past 13 years, the highest Beneish M-Score of Daito Pharmaceutical Co was -2.29. The lowest was -2.75. And the median was -2.60.


Daito Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Daito Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daito Pharmaceutical Co Beneish M-Score Chart

Daito Pharmaceutical Co Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.62 -2.29 -2.47 -2.58 -2.46

Daito Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.46 0.00 0.00 0.00

TSE:4577 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daito Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Daito Pharmaceutical Co's Beneish M-Score falls into.


TSE:4577
71GF Score
Daito Pharmaceutical Co Ltd TSE:4577
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daito Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Daito Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0831+0.528 * 1.2302+0.404 * 1.0414+0.892 * 1.0799+0.115 * 0.8571
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.051138-0.327 * 1.0213
=-2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (May25) TTM:Last Year (May24) TTM:
Total Receivables was 円12,669 Mil.
Revenue was 円50,643 Mil.
Gross Profit was 円8,637 Mil.
Total Current Assets was 円41,708 Mil.
Total Assets was 円78,004 Mil.
Property, Plant and Equipment(Net PPE) was 円31,826 Mil.
Depreciation, Depletion and Amortization(DDA) was 円4,332 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円17,049 Mil.
Long-Term Debt & Capital Lease Obligation was 円8,428 Mil.
Net Income was 円1,908 Mil.
Gross Profit was 円0 Mil.
Cash Flow from Operations was 円5,897 Mil.
Total Receivables was 円10,831 Mil.
Revenue was 円46,895 Mil.
Gross Profit was 円9,839 Mil.
Total Current Assets was 円41,460 Mil.
Total Assets was 円77,708 Mil.
Property, Plant and Equipment(Net PPE) was 円31,972 Mil.
Depreciation, Depletion and Amortization(DDA) was 円3,659 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円18,505 Mil.
Long-Term Debt & Capital Lease Obligation was 円6,345 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12669 / 50643) / (10831 / 46895)
=0.250163 / 0.230963
=1.0831

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9839 / 46895) / (8637 / 50643)
=0.209809 / 0.170547
=1.2302

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (41708 + 31826) / 78004) / (1 - (41460 + 31972) / 77708)
=0.057305 / 0.055027
=1.0414

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=50643 / 46895
=1.0799

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3659 / (3659 + 31972)) / (4332 / (4332 + 31826))
=0.102691 / 0.119808
=0.8571

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 50643) / (0 / 46895)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8428 + 17049) / 78004) / ((6345 + 18505) / 77708)
=0.326611 / 0.319787
=1.0213

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1908 - 0 - 5897) / 78004
=-0.051138

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Daito Pharmaceutical Co has a M-score of -2.46 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.46 mean?
Daito Pharmaceutical Co (TSE:4577) has a Beneish M-Score of -2.46 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Daito Pharmaceutical Co and its competitors. According to the industry distribution chart, Daito Pharmaceutical Co ranks #485 out of 911 companies in the Drug Manufacturers industry, placing it in the top 53.2%.
Is Daito Pharmaceutical Co's Beneish M-Score too high?
Daito Pharmaceutical Co's current Beneish M-Score is -2.46. Based on the distribution chart, Daito Pharmaceutical Co ranks #485 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Daito Pharmaceutical Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #485 out of 911 companies for Beneish M-Score. This places Daito Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Daito Pharmaceutical Co and its competitors. Daito Pharmaceutical Co's current Beneish M-Score is -2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,276.34, compared to a current price of 円1,224.00 — trading 4.1% below its estimated fair value. The current Beneish M-Score is -2.46. Daito Pharmaceutical Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current Beneish M-Score is -2.46 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?

Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,224.00 is trading 4.1% below its estimated GF Value™ of 円1,276.34. GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4577:

  • Beneish M-Score: -2.46
  • GF Value™: 円1,276.34 vs. price of 円1,224.00 (4.1% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Daito Pharmaceutical Co Business Description

Address 326 Yokamachi, Toyama, JPN, 939-8567
Daito Pharmaceutical Co Ltd is engaged in the research and development of pharmaceutical products. The company also undertakes contract manufacturing.
71GF Score

Get the complete analysis for TSE:4577

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,224.00
Price
円1,276.34
GF Value